anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the title compound, useful as an antiphlogistic agent and an immunity activator, by reducing threo-3-amino-2-hydroxy-4-oxo-4-phenylbutyric acid, etc., and if necessary removing an amino-protecting group or an ester residue, condensing the product with aminoacetic acid, etc. CONSTITUTION:Compounds of formula II are obtained by the catalytic reduction of threo-3-amino-2-hydroxy-4-oxo-4-phenylbutyric acid or its esters of formula I (R1 is H or OH; R2 is protected amino; R3 is H or an ester residue) with Pd, etc. in a solvent such as acetic acid, at 40-70 deg.C. Subsequently, when the compounds II are (2S,3R)-type compounds, an amino-protecting group is removed if necessary, and an ester residue is removed if it is present, whereby compounds of formula III (R2' is amino or protected amino) are obtained. Then, the compounds III and aminoacetic acid of formula IV (R4 is 3-4C alkyl, etc.) are condensed, protecting a functional group which does not participate in the reaction. After the reaction, the protecting group is removed, to obtain compounds of formula V.
Long-term studies in animals have not been performed to evaluate carcinogenic potential.

Animal reproduction studies have not been conducted with Sodium Sulfacetamide Lotion. It is also not known whether Sodium Sulfacetamide Lotion can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Sulfacetamide Lotion should be given to a pregnant woman only if clearly needed.

Kernicterus may occur in the newborn as a result of treatment of a pregnant woman at term with orally administered sulfonamide. There are no adequate and well-controlled studies of Sodium Sulfacetamide Lotion in pregnant women, and it is not known whether topically applied sulfonamides can cause fetal harm when administered to a pregnant woman.
Preterm children present more cognitive impairments, psychological and behavioral problems, motor and coordination impairments than their term counterparts. These impairments may cause the difficulties of learning and adaptation at the school age when facing multiple and complicate environmental stimulations in preterm children. Accumulating data on early intervention for preterm infants in Eastern and Western countries have demonstrated short- to medium-term benefits on enhancing child neurodevelopment outcomes. However, rare studies have examined the effectiveness of early intervention for preterm infants and its underlying neural mechanism. To meet the contemporary concept of family centered care, we have developed a family-centered intervention program (FCIP) for preterm infants with very low birth weight (VLBW, birth weight \<1,500 g) in Taiwan and have found short-term developmental benefit with respect to a usual care program (UCP) via a multi-centered, randomized controlled trial. Therefore, this three-year project is aimed to continuously follow-up the effectiveness of FCIP on child and parent outcomes in VLBW preterm infants at school age. A total of 275 VLBW preterm children (269 participants and 6 pilots) who had participated in our previous randomized controlled study and 45 term children will be assessed growth, health, neurobehavioral functions (cognition, language, motor and behaviors), electroencephalography and event-related potentials (in the resting state, cognitive inhibitory control and working memory procedures) and cognition/motor dual tasks at 7 years of age. Parents will be assessed for stress using the Parenting Stress Index/Long Form and quality of life with the World Health Organization Quality of Life- Brief Taiwan Version. The effect of early intervention for preterm children from the neonatal period to school age will provide important information to help medical professionals and public policy makers design effective intervention for Taiwanese preterm children. The continuous neurophysiological and neurobehavioral data are crucial for understanding the neurophysiological mechanisms underlying neurobehavioral changes following intervention.
A thermal promoter that can be used as a drug delivery vehicle to deliver one or more drugs to a target site. For example, in certain embodiments, a carrier such as albumin or Human Serum Albumin (HSA) may be impregnated with or covalently linked to an anti-tumor agent and delivered to a location proximal to a tumor in a patient. The carrier may be exposed to an energy source that structurally alters the carrier and releases the agent therefrom. The energy source may include one or more of microwaves, radio frequency, electrical pulses (electroporation) or sonar (HIFU or histotripsy). In certain embodiments, the anti-neoplastic agent may be released with a delay such that a portion of the agent is released from the carrier over an extended period of time. Incorporation of an antineoplastic agent into a thermal accelerator provides a thermal ablation-drug delivery combination therapy (e.g., a thermal activation combination therapy).
Mutations in Dystonin (DST), which encodes cytoskeletal linker proteins, cause hereditary sensory and autonomic neuropathy 6 (HSAN-VI) in humans and the dystonia musculorum (dt) phenotype in mice; however, the neuronal circuit underlying the HSAN-VI and dt phenotype is unresolved. dt mice exhibit dystonic movements accompanied by the simultaneous contraction of agonist and antagonist muscles and postnatal lethality. Here, we identified the sensory-motor circuit as a major causative neural circuit using a gene trap system that enables neural circuit-selective inactivation and restoration of Dst by Cre-mediated recombination. Sensory neuron-selective Dst deletion led to motor impairment, degeneration of proprioceptive sensory neurons, and disruption of the sensory-motor circuit. Restoration of Dst expression in sensory neurons using Cre driver mice or a single postnatal injection of Cre-expressing adeno-associated virus ameliorated sensory degeneration and improved abnormal movements. These findings demonstrate that the sensory-motor circuit is involved in the movement disorders in dt mice and that the sensory circuit is a therapeutic target for HSAN-VI.
New patients who come into the orofacial pain clinic are evaluated by a dental resident and given an orofacial pain diagnosis. If this primary diagnosis involves masticatory myofascial pain, local myalgia, or centrally-mediated myalgia, and if patients self-report poor sleep, they will be introduced to the study. An initial evaluation for PSR and BBTI will be scheduled over telehealth. If willing and eligible to participate, at the end of this first evaluation, they will be provided with an informed consent form and be randomly assigned to three sessions of PSR or three sessions of BBTI. After providing an e-consent, they will be sent a questionnaire battery on REDCap to assess their outcomes at pre-intervention. A REDCap daily questionnaire will be sent every day (morning and evening) starting one week before session 1 of the intervention, until two weeks after the last session. Moreover, to a small group of patients randomly selected, an actigraphy watch will be mailed. Two weeks after the last session of the intervention, a REDCap questionnaire will be sent to assess their outcomes at post-intervention. As per the current clinical protocol, all participants will be offered both interventions; only data from the first intervention will be utilized for the current study. All PSR and BBTI sessions will be conducted via telehealth using a HIPAA-compliant zoom account.
A parental history of an eating disorder is linked with greater risk of eating and socio-emotional problems in the offspring, and more stressful parent-child interactions. Further, parenting concerns often exacerbate existing eating disorder symptoms in parents. Parent-Based Prevention (PBP-B) is a focused intervention aimed to support parents with eating disorders and their partners in developing healthy eating and lifestyle behaviors in their children. The program also focuses on reducing mealtime conflict and improving couple communication. This study tests the feasibility, acceptability and preliminary outcomes of the Parent-Based Prevention (PBP) program for these parents and their partners. Parents with any lifetime eating disorder diagnosis who have at least one child 1-5 years old will be randomized to receive PBP immediately or following a 16-week waitlist period. This study will investigate whether PBP is feasible, acceptable, and associated with improvement in short-term outcomes that predict long term risks of eating and weight disorders (e.g., parental cognition associated with feeding practices and child eating behaviors and socio-emotional symptoms). The study will collect important case series data that will inform the design of larger, adequately powered studies to test ways to reduce the likelihood of eating and weight difficulties in the offspring of parents with eating disorders.
NEW MATERIAL:A specific antigen protein from Bacteroides ginvalis, having the amino acid sequence given in the formula. USE:An immunological diagnostic for adult periodontitis. PREPARATION:For example, the DNA containing the specific antigen gene originating from Bacteroides ginvalis coding the amino acid sequence given in the formula is bonded to an appropriate vector to prepare a recombined plasmid. The host such as Escherichia coli is transformed by plasmid insertion, inoculated in a culture medium and subjected to shake culture. The culture mixture is centrifuged to collect the cell bodies, which are dispersed in a buffer and crushed by means of ultrasonic vibration. The product is centrifuged to collect the supernatant, the supernatant is saturated with ammonium sulfate and gel-filtered to obtain the subject antigen protein with the amino acid sequence given in the formula.
Risperidone oral solution contains risperidone, an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. The chemical designation is 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one. Its molecular formula is C23H27FN4O2 and its molecular weight is 410.49. The structural formula is:

Risperidone is a white or almost white powder. It is practically insoluble in water, freely soluble in methylene chloride and soluble in methanol and 0.1 N HCl.

Risperidone is available as a 1 mg/mL oral solution. The inactive ingredients for this solution are benzoic acid, sodium hydroxide, sorbitol solution, purified water and tartaric acid.
A smart health management system for a telemedicine service at least includes a personalized medical management module, a telemedicine service module, a medical examination and equipment management module and an insurance service module. A medical service demander can provide a medical diagnosis service request through the personalized medical management module. Moreover, the medical service demander and the telemedicine service module perform a telemedicine diagnosis service. Moreover, the medical examination and equipment management module is used to acquire a pathological inspection and imaging examination information. Consequently, the telemedicine service module generates a medical diagnosis information and a drug prescription information in response to the medical examination and equipment management module. Moreover, in response to a medical insurance request and an electronic medical record, the insurance service module generates an insurance claim information automatically.
The present invention provides an immunogenic composition comprising a fusion protein and a saponin adjuvant. The fusion protein comprises a heterologous hydrophobic peptide that is fused to the N-terminus and/or to the C-terminus of a core polypeptide. The core polypeptide comprises at least one protective epitope. The saponin adjuvant in this composition is present in a free form. Also provided are vaccines comprising the immunogenic composition and optionally an additional immunoactive component. Methods for the preparation of such vaccines, and use of the immunogenic composition for the manufacture of a vaccine are provided as well.
An imaging system provider provides updates to an imaging facility. These updates are referred to as configurations, and each configuration has an associated date-time. The provider stores each configuration and its date-time in a blockchain. When the imaging facility acquires an image of a patient, the image is watermarked with an identification of the configuration of the imaging system at the time the image was acquired. When the patient wants to verify whether the image was taken using the most up to date configuration, the patient submits an identification of the image to a verification system. The verifier submits a request for proof from the imagining facility. The imaging facility compares the watermarked information and the information in the block chain, and provides the proof to the verification system, which verifies the proof. To assure privacy and security, a zk-SNARK is used for the proving and verification processes.
An injectable anti-influenza drug peramivir has been reported to induce QT-interval prolongation in some phase III studies, although its thorough QT/QTc study was negative. We investigated the discrepancy among those clinical studies using isoflurane-anesthetized beagle dogs (n = 4). Peramivir in doses of 1 mg/kg/10 min (sub-therapeutic dose) followed by 10 mg/kg/10 min (clinically-relevant dose) was intravenously administered. Peramivir prolonged QT interval/QTcV and Tpeak-Tend, and tended to delay ventricular repolarization in a reverse-frequency dependent manner, indicating IKr inhibition in vivo. Meanwhile, peramivir did not alter P-wave duration, PR interval or QRS width, indicating a lack of impact on cardiac conduction via Na+ or Ca2+ channel inhibition in vivo. Peramivir prolonged Tpeak-Tend and tended to prolong terminal repolarization period, which would develop substrates for initiating and maintaining spiral reentry, respectively. Meanwhile, peramivir did not prolong J-Tpeakc, which could not induce early afterdepolarization, a trigger inducing torsade de pointes. Thus, our results support that clinical dose exposure of peramivir can delay the ventricular repolarization in influenza patients. Peramivir has only a small potential to induce torsade de pointes in patients with the intact hearts, but caution should be paid on its use for patients formerly having the trigger for torsade de pointes.
NATURE is an open label, neoadjuvant, phase II study designed to evaluate the objective response rate of trastuzumab emtansine in patients with newly diagnosed HER2-equivocal breast cancer. Patients will receive trastuzumab emtansine at a dose of 3.6 mg/kg via intravenous infusion every 3 weeks for a total of 6 weeks (2 21-day cycles). Patients who achieve partial or complete response (responders) after the 6-week treatment will continue on trastuzumab emtansine for an additional 12 weeks (4 cycles). The primary objective will be objective response rate after 6 weeks of neoadjuvant trastuzumab emtansine. Secondary objectives will include imaging response (ultrasound and magnetic resonance imaging) after six weeks of neoadjuvant trastuzumab emtansine and toxicity and efficacy of trastuzumab emtansine. After completion of continued trastuzumab emtansine treatment, pathological complete response rate of responders as a whole and according to estrogen receptor status will be explored. Markers related to the mechanism of action of trastuzumab emtansine (HER2 copy number in circulating tumor cells; tissue expression of PTEN, PI3K, and other potential candidate markers) will also be explored.
All routes of administration of BREVITAL are often associated with hiccups, coughing, and/or muscle twitching, which may also impair pulmonary ventilation. Following induction, temporary hypotension and tachycardia may occur.

Recovery from methohexital anesthesia is rapid and smooth. The incidence of postoperative nausea and vomiting is low if the drug is administered to fasting patients. Postanesthetic shivering has occurred in a few instances.

The usual precautions taken with any barbiturate anesthetic should be observed with BREVITAL. The drug should be used with caution in patients with asthma, obstructive pulmonary disease, severe hypertension or hypotension, myocardial disease, congestive heart failure, severe anemia, or extreme obesity.

Methohexital sodium should be used with extreme caution in patients in status asthmaticus. Caution should be exercised in debilitated patients or in those with impaired function of respiratory, circulatory, renal, hepatic, or endocrine systems.
This is a longitudinal study which aims to examine the short- and long-term eating difficulties, its related factors and its impacts. The participants will be recruited in the outpatient department of Ear, Nose, and Throat (ENT) in NTUH. The inclusion criteria are (a) diagnosed as head and neck cancer; (b) will be received cancer treatments including surgery and CCRT; (c) age is 20 or older. The exclusion criteria are (a) the patient is inserted a plastic tube, e.g. nasogastric tube (NG) or percutaneous endoscopic gastrostomy tube (PEG), for feeding; (b) patients could not understand the content of questionnaires. The investigators will recruit 100 subjects with complete 12-month data. Concerning 25% patients loss rate, the investigators will recruit 125 subjects at the beginning of the first year.

Patients will be assessed by Chewing Swallowing Inventory (CSI), Mini Nutritional Assessment (MNA), Depression subscale of Hospital Anxiety and Depression Scale (HADS), Symptom Severity Scale (SSS), 0-10 general Fatigue severity numerical scale, and disease and treatment background Information Form (BIF). Grip power of dominant hand will be assessed by hand dynamometer.
DESIGN: A retrospective, uncontrolled, questionnaire-based, pre-post study involving adult male smoker volunteers who were invited to attend a one-day smoking cessation event at their workplace.
OBJECTIVE: To assess the effect of feedback on motivation for smoking cessation using oral-malodor measurements.
METHODS: At baseline, the participants attended a brief video presentation regarding various oral health-specific effects of smoking, joined a group introduction to smoking-cessation aids, and were given questionnaires that inquired information about smoking status including type, daily consumption, and duration. Subsequently, respiratory function and oral-malodor assessment were conducted using exhaled and oral cavity air, respectively. To measure oral-malodor, hydrogen sulfide, methyl mercaptan, and dimethyl sulfide concentrations were determined. Participants' intention for smoking cessation was evaluated through questionnaire before and after the event, classifying their intentions as aiming to quit within the next month, within the next 6 months, or having no intention to quit smoking. Immediate feedback on respiratory function and oral malodor measurements was provided by medical and dental blinded examiners, respectively.
RESULTS: A total of 241 men, aged 20-54 years, were enrolled and included: 169 (70.1%) exclusive cigarette smokers, 39 (16.2%) exclusive heated-tobacco product users, and 33 (13.7%) users of both. Prior to the health event, 8.7%, 17.0%, and 74.3% of smokers expressed intentions to quit within the next month, the next 6 months, or had no intention to quit, respectively. After the event, the corresponding percentages shifted to 17.8%, 26.6%, and 55.6%. In multivariable logistic regression analysis, the association with intention to quit in the next month was significant only for methyl mercaptan concentration in oral cavity air, with an adjusted odds ratio (AOR) of 4.24 (95% CI: 1.52-11.84; p = 0.006). Sensitivity analysis revealed that this association was concentration-dependent. On the other hand, higher daily tobacco consumption (≥ 15 pieces) was significantly associated with less likely intention to quit in the next 6 months (AOR = 0.37; 95% CI: 0.15-0.92, p = 0.032).
CONCLUSION: Feedback on oral malodor measurement may support the motivation of men to quit smoking within the next month, rather than waiting for the next 6 months.
Overall aim of this program of research is to develop and evaluate the "Teens Taking Charge: Managing Cancer Online" Internet intervention that will help AWC to better cope with their disease, improve their HRQL, and enhance readiness to transition to adult health care using a sequential phased approach. The first phase of this project has determined the self-management and transitional care needs of adolescents with cancer. The second phase consisted of website development and usability testing to ensure the website is easy to use and understand, and is efficient and satisfying to complete. Subsequently, we will assess the feasibility of the program and the outcomes from the use of the site in a randomized controlled trial (RCT) pilot study (Phase 3). This will inform the design and methods of the main trial, and will permit us to obtain estimates of treatment effects on AWC health outcomes to inform the calculation of an appropriate sample size for the future definitive RCT (Phase 4). The focus of this study is Phase 3. Phase 4 will be a multicentre randomized controlled trial to assess outcomes for teens that complete the intervention as compared to those of an attention control group.
PURPOSE:To improve the diagnosis and remedy of colon cancer by recognizing a reg protein which is human and/or rat reg protein. CONSTITUTION:(A) An antibody-producing cell produced by immunizing a mouse, etc., with a fused protein obtained by the fusion of a reg protein and human IFNgamma is fused with (B) a desired myeloma cell and the fused cell is screened to obtain (C) hybridoma REG 5, REG 17, REG 30, HREG NI and HREG 9. The component C is cultured e.g. in Dalbecco's modified medium containing bovine fetus serum for 3-5 days. The supernatant of the obtained cultured product is purified by ammonium sulfate fractionation, gel-filtration, etc., to obtain (D) a monoclonal antibody recognizing a reg protein selected from monoclonal antibody REG 5, REG 17, REG 30, HREG NI and HREG 9. As necessary, reg protein is immunologically determined by sandwich EIA method, etc., using the component D.
Veterinary vaccines comprise a suspension of antigens of viral and/or bacterial origin, at least one of which is a live vaccine and the remainder of which is in the form of a killed vaccine or antigenic derivatives thereof.  Specified combinations include; modified hog cholera vaccine (live) and swine erysipelas bacterin (dead), brucella abortus (live) and black leg bacterin (dead), canine distemper vaccine (live, viral) and canine hepatitis (dead viral), swine erysipelas bacterin (live) and Brynton's (anti-hog cholera) tissue vaccine (dead viral), hog cholera vaccine (live) and E-rhusiopathial (dead).  The antigens may be present absorbed on suitable agents e.g. aluminium hydroxide or phosphate, aluminium potassium sulphate, tannic acid, calcium phosphate. Killing or preserving agents which may adversely effect the live vaccine should be absent and as killing agents these are referred to soluble salts of penicillin, ultra violet radiation, heat and formalin (inactivated by neutralzation e.g. with buffered ammonium hydroxide).